Discover
MAIA
MAIA Biotechnology, Inc.
1.43
1700 x 1.42
5000 x 1.51
bid
ask
-
0.01
0.69%
3350 @ 04:00 PM
1.43 +0.00 (0.00%)
| Ytd | -6.54% | |
| 1y | -25.52% |
1.40
day range
1.46
0.87
52 week range
3.19
| Open | 1.40 | Prev Close | 1.44 | Low | 1.40 | High | 1.46 | Mkt Cap | 86.95M |
| Vol | 255.73K | Avg Vol | 745.35K | EPS | -0.68 | P/E | N/A | Forward P/E | -1.25 |
| Beta | 0.34 | Short Ratio | 10.99 | Inst. Own | 7.51% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-08 | 50-d Avg | 1.33 | 200-d Avg | 1.49 | 1yr Est | 12.63 |
MAIA News
benzinga.com
MAIA Biotechnology Completes Global Enrollment In Part C Of Its Phase 2 THIO-101 Expansion Study Of
MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage bioph
globenewswire.com
MAIA Biotechnology Completes International Enrollment in Part C of Phase 2 THIO-101 Expansion Trial
Part C domestic enrollment is underway at three clinical sites in the U.S. CHICAGO, June 25, 2026 (G
benzinga.com
MAIA Biotechnology Provides A Patient Enrollment Update For Its Ongoing Pivotal Phase 3 Trial, THIO-
MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage bioph
benzinga.com
MAIA Biotechnology Receives FDA IND Clearance To Expand THIO-101 Phase 2 NSCLC Trial In U.S. With At
Additional data from THIO-101 trial expansion studies may further support a potential Accelerated Ap
benzinga.com
MAIA Biotechnology Insiders Founder/CEO Vlad Vitoc, M.D. And Director Stan V. Smith, Ph.D. Increase
Approximately 72,700 shares of MAIA common stock were purchased by Dr. Vitoc on June 6, 2026, at an
benzinga.com
MAIA Biotechnology Announces That It Delivered A Poster Presentation Featuring The Methodology And S
THIO-104 evaluates the efficacy of MAIA's telomere targeting agent, ateganosine, administered in